Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.
The University of Zürich is a public research university located in the city of Zürich, Switzerland. It is the largest university in Switzerland, with its 28,000 enrolled students. It was founded in 1833 from the existing colleges of theology, law, medicine which go back to 1525, and a new faculty of philosophy.
The University of Basel is a university in Basel, Switzerland. Founded on 4 April 1460, it is Switzerland's oldest university and among the world's oldest surviving universities. The university is traditionally counted among the leading institutions of higher learning in the country.
Paul Hermann Scherrer was a Swiss physicist. Born in St. Gallen, Switzerland, he studied at Göttingen, Germany, before becoming a lecturer there. Later, Scherrer became head of the Department of Physics at ETH Zurich.
The University of Bern is a university in the Swiss capital of Bern and was founded in 1834. It is regulated and financed by the Canton of Bern. It is a comprehensive university offering a broad choice of courses and programs in eight faculties and some 150 institutes. With around 19,000 students, the University of Bern is the third largest university in Switzerland.
The Basel Institute for Immunology (BII) was founded in 1969 as a basic research institute in immunology located at 487 Grenzacherstrasse, Basel, Switzerland on the Rhine River down the street from the main Hoffmann-La Roche campus near the Swiss-German border. The institute opened its doors in 1971.
Daniel Lucius Vasella is a Swiss medical doctor, author, and executive who served as CEO and chairman of the Swiss pharmaceutical company Novartis AG, the world's fifth largest drug company. During his tenure Novartis shares fell 10%, compared to the industry average. In February 2013 Vasella was awarded close to $78 million in a "golden handshake"
Gerald Francis "Jerry" Joyce is president and professor at the Salk Institute for Biological Studies and was previously the director of the Genomics Institute of the Novartis Research Foundation. He is best known for his work on in vitro evolution, for the discovery of the first DNA enzyme (deoxyribozyme), for his work in discovering potential RNA world ribozymes, and more in general for his work on the origin of life.
Philippa "Pippa" Marrack, FRS is an English immunologist and academic, based in the United States, best known for her research and discoveries pertaining to T cells. Marrack is the Ida and Cecil Green Professor and chair of the Department of Biomedical Research at National Jewish Health and a distinguished professor of immunology and microbiology at the University of Colorado Denver.
The Graduate Institute of International and Development Studies, or the Geneva Graduate Institute, abbreviated IHEID, is a government-accredited postgraduate institution of higher education located in Geneva, Switzerland.
Thaddeus P. Dryja is an American ophthalmologist and geneticist known for his role in the 1986 discovery of the Rb tumor suppressor gene. He was the David G. Cogan Professor of Ophthalmology at Harvard University and was the Global Head of Ophthalmology Research at Novartis. He was elected a member of the National Academy of Sciences in 1996.
The Novartis Institute for Tropical Disease (NITD) was a Singapore-based tropical disease research institute created through a public-private partnership between Novartis and the Singapore Economic Development Board. Research at NITD focuses primarily on developing novel small molecule therapies for tropical infectious diseases that are endemic to the developing world, particularly dengue fever, malaria and tuberculosis.
Mark Fishman is an American cardiologist, a professor in the Harvard Department of Stem Cell and Regenerative Biology and Chief of the Pathways Clinical Service service at the MGH for patients with complex medical disorders. A researcher and clinician in cardiology, he is the previous president of the Novartis Institutes for BioMedical Research (NIBR), the main research arm of Novartis Pharmaceuticals.
Frederick W. Alt is an American geneticist. He is a member of the Immunology section of the National Academy of Sciences and a Charles A. Janeway Professor of Pediatrics, and Professor of Genetics at Harvard Medical School. He is the Director of the Program in Cellular and Molecular Medicine at the Boston Children's Hospital. He is a Howard Hughes Medical Institute investigator, since 1987.
Laurence Harris Pearl FRS FMedSci is a British biochemist and structural biologist who is currently Professor of Structural Biology in the Genome Damage and Stability Centre and was Head of the School of Life Sciences at the University of Sussex.
Arthur Stoll was a Swiss biochemist.
Carl H. June is an American immunologist and oncologist. He is currently the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine of the University of Pennsylvania. He is most well known for his research on T cell therapies for the treatment of several forms of cancers. In 2020 he was elected to the American Philosophical Society.
Nathanael S. Gray is a Krishnan-Shah Family Professor of chemical and systems biology at Stanford University and director of cancer therapeutics programme at Stanford University School of Medicine. Previously he was a Nancy Lurie Marks Professor of biological chemistry and molecular pharmacology at Harvard Medical School and professor of cancer biology at Dana–Farber Cancer Institute. Gray is also co-founder, science advisory board member (SAB) and equity holder in C4 Therapeutics, Gatekeeper, Syros, Petra, B2S, Aduro, Jengu, Allorion, Inception Therapeutics, and Soltego. C4 Therapeutics, which offered IPO in 2020, was founded based on the ground-breaking research of Jay Bradner, current president of Novartis Institutes for BioMedical Research (NIBR), and of Nathanael S. Gray, while he was professor at Harvard Medical School. Before moving to Stanford University, Nathanael S. Gray created Center for Protein Degradation at Harvard Medical School with $80 million agreement with Deerfield Management venture capital firm. In 2020, Gray Lab permanently moved to Stanford University, that was stated by Stuart Schreiber, co-founder of Broad Institute as "Stanford's huge gain".
Rudolf Geigy was a Swiss biologist and a professor of embryology and genetics at the University of Basel. He established the Swiss Tropical and Public Health Institute and studied tropical diseases.
Jean-François Borel is a Belgian microbiologist and immunologist who is considered one of the discoverers of cyclosporin.
